GlassScriptPhysician profile
Thomas J Desperito
NPI 1265536353
$7,137.54
in general payments reported to CMS, 2019-2025
36 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,531 · 2020: $342 · 2021: $729 · 2022: $612 · 2023: $1,434 · 2024: $1,428 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,850 · Travel and Lodging: $74.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,849.64 |
| Travel and Lodging | $74.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,590.94 | 2021-2025 | Interstim |
| Neotract INC. | $1,385.77 | 2019-2020 | |
| Teleflex LLC | $549.10 | 2021-2024 | Urolift |
| Pfizer INC. | $392.16 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $362.23 | 2023-2025 | Orgovyx, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $248.70 | 2021-2025 | |
| Astellas Pharma US INC | $245.91 | 2019-2024 | Myrbetriq, Xtandi |
| Axonics, INC. | $218.34 | 2020-2024 | Axonics |
| Procept Biorobotics Corporation | $171.27 | 2025 | |
| Medtronic USA, INC. | $166.82 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $165.76 | 2024-2025 | Adstiladrin |
| Novartis Pharmaceuticals Corporation | $153.08 | 2025 | |
| Urogen Pharma, INC. | $130.03 | 2022-2024 | Jelmyto |
| Calyxo, INC. | $128.98 | 2025 | Cvac Aspiration System |
| Tolmar, INC. | $121.38 | 2023-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $119.51 | 2023-2024 | Erleada, Akeega |
| Myriad Genetic Laboratories, INC. | $109.08 | 2022-2024 | Prolaris |
| Myovant Sciences INC. | $102.45 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $93.94 | 2022-2025 | Lynparza |
| Abbvie INC. | $82.26 | 2021-2025 | |
| 180 Medical, INC. | $77.88 | 2021 | |
| Progenics Pharmaceuticals, INC. | $65.37 | 2023-2024 | Pylarify |
| Valencia Technologies Corporation | $50.00 | 2022 | |
| Civco Medical Instruments | $49.62 | 2025 | |
| Photocure INC | $45.89 | 2025 | Cysview |
| Urovant Sciences INC | $43.47 | 2021-2022 | |
| Telix Pharmaceuticals | $40.24 | 2023-2024 | Illuccix |
| Acerus Pharmaceuticals Corporation | $37.83 | 2020-2021 | |
| Bluewind Medical | $32.88 | 2024 | Revi |
| Dendreon Pharmaceuticals LLC | $31.11 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $28.60 | 2023 | Seglentis |
| Blue Earth Diagnostics | $23.41 | 2024 | |
| Accord Healthcare, INC. | $21.83 | 2023 | |
| Azurity Pharmaceuticals, INC. | $20.40 | 2025 | Azmiro |
| Olympus America INC. | $19.33 | 2025 | Soltive |
| Endo Pharmaceuticals INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Desperito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.